Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. I. Park, S. Y. Kim, J. O. Kim, S. S. Jung, H. S. Park, J. Y. Moon, C. U. Chung, J. E. Lee (Daejeon, Republic Of Korea). The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib. Eur Respir J 2014; 44: Suppl. 58, 1930

Member's Comments

No comment yet.

Related content which might interest you: Role of mean sUV and metabolic tumor volume by PET/CT for determination of mean survival time in patients with non-small cell lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Neutrophil/lymphocyte ratio as a prognostic marker for curative-intent surgery in non-small cell lung cancer Source: International Congress 2015 – Surgery and lung cancer: results and complications Year: 2015 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Locoregional recurrence after pulmonary segmentectomy of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Preoperative FDG uptake on PET/CT predicts disease recurrence and survival in early stage non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Algorithm of preoperative N-staging of non-small cell lung cancer Source: Annual Congress 2013 –Oncological thoracic surgery Year: 2013 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014